By Dan Schell, Chief Editor, Clinical Leader
Mary Szela is president and CEO of TriSalus Life Sciences, an emerging immuno-oncology company developing treatments for patients with solid tumors. She has more than 30 years of biopharma experience, including spending 25 years at Abbott, where she held ascending management positions, including president of the company’s $8 billion U.S. pharmaceutical business. During the last seven years, she has held CEO positions at Melinta Pharmaceuticals, Novelion Therapeutics, and now TriSalus. With that kind of experience, we asked her to participate in the following Q&A to offer our readers some valuable insights about what it takes to transition from Big Pharma to a CEO position at a smaller biotech.